ArticlePloS one2025
Alkaloid production of Solanum elaeagnifolium Cav from callus for anticancer potential using gene expression of cancer-related genes.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the major diseases that threaten human life and causes death for many people worldwide. Some alkaloids derived from plants show promising potential for cancer treatment. Solanaceae family is of these plants that have promising alkaloid. In this study alkaloid production from Solanum elaeagnifolium callus cultures was investigated and their anticancer properties were evaluated. Optimal callus growth and alkaloid production were achieved in media enriched with a combination of BAP and 2,4-D at a ratio of 1.0:1.0 mg/L. LC-MS/MS analysis showed that β-Solamargine, tomatidenol, Solasonine, solanidine and solasodine are the most important alkaloids of Solanum elaeagnifolium. Moreover, the analysis revealed that β-Solamargine is the predominant alkaloid (78.7%) in callus extracts. The results of MTT assay, demonstrated that the most effective response were obtained from callus extracts medium containing a balanced concentration of BAP and 2,4-D, and it yielding an IC50 of 6.25 µl/ml. In contrast, lower efficacy was observed with IC50 values of 25 and 50 µl/ml, when callus medium were supplemented with NaCl and yeast extract, respectively. Gene expression analysis shows an increase in the Bax/Bcl-2 ratio following 24 h of the extracts treatment. Along with a down regulation of CDK1 gene expression in comparison to untreated MCF7 cells, the CDK1 levels were elevated. Alkaloids derived from S. elaeagnifolium may be a promising candidate for anticancer therapy; further investigation is needed in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.